Join the 'Leukemia' group to help and get support from people like you.
Leukemia News
Related terms: Cancer, Leukemia
FDA Expands Approval of Blincyto (blinatumomab) to Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
Posted 14 days ago by Drugs.com
March 29, 2018 – The U.S. Food and Drug Administration granted accelerated approval to Blincyto (blinatumomab) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD). MRD refers to the presence of cancer cells below a level that can be seen under the microscope. In patients who have achieved ...
Novartis Drug Tasigna Approved by FDA to Treat Children with Rare Form of Leukemia
Posted 14 days ago by Drugs.com
Basel, March 22, 2018 - Novartis announced today that the US Food and Drug Administration (FDA) expanded the indication for Tasigna (nilotinib) to include treatment of first- and second-line pediatric patients one year of age or older with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP). In the United States, Tasigna is now indicated for the treatment ...
FDA Approves Pfizer’s Bosulif (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)
Posted 9 Jan 2018 by Drugs.com
December 19, 2017 – Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indication for Bosulif (bosutinib) to include adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). The sNDA was reviewed and approved under the FDA’s Priority R ...
FDA Updates the Label of Tasigna to Reflect that Certain Patients with a Type of Leukemia May be Eligible to Stop Treatment After Sustained Response
Posted 30 Dec 2017 by Drugs.com
December 22, 2017 – The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotinib) to include information for providers about how to discontinue the drug in certain patients. Tasigna, first approved by the FDA in 2007, is indicated for the treatment of patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). With today’s u ...
Health Tip: Schooling While Managing Cancer
Posted 29 Dec 2017 by Drugs.com
-- Homework may not be the number one priority when your child is being treated for cancer. But school shouldn't be forgotten. Many children with cancer consider school and spending time with other kids as a sign of normalcy, the American Cancer Society says. The society offers these suggestions for keeping up with school during treatment: Request home instruction for your child. In many cases, ...
Health Tip: Talking With Your Child's Cancer-Care Team
Posted 16 Nov 2017 by Drugs.com
-- If your child has cancer and is being treated by a team of specialists, frequent and open communication is essential. The American Cancer Society suggests how to talk with team members: Actively take part in your child's care. Communication should be clear, direct and honest. Treat team members with respect. Provide thorough and accurate information about your child's health history. Address ...
Health Tip: Accept Help if Your Child Has Cancer
Posted 9 Nov 2017 by Drugs.com
-- Caring for a child with cancer can be emotionally and physically overwhelming. The Children's Oncology Group says the best thing such a parent can do is to accept help from friends and family. The group mentions these benefits of doing so: You will have more energy to take care of your child, spend time with your other children and connect with your partner. While there are some things that ...
Are You Sure That's What the Doctor Said About Your Leukemia?
Posted 3 Nov 2017 by Drugs.com
THURSDAY, Nov. 2, 2017 – The stress of a frightening leukemia diagnosis may impede clear doctor-patient communication, a new study suggests. Patients undergoing chemotherapy treatment for acute myeloid leukemia (AML) tend to view their illness and prognosis through a different lens from their doctors, researchers say. Investigators found that patients are inclined to overestimate their risk of ...
FDA Approves Mylotarg (gemtuzumab ozogamicin) for the Treatment of Acute Myeloid Leukemia
Posted 1 Sep 2017 by Drugs.com
September 1, 2017 – The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not ...
FDA OKs Return of Once-Withdrawn Leukemia Drug, Mylotarg
Posted 1 Sep 2017 by Drugs.com
FRIDAY, Sept. 1, 2017 – The U.S. Food and Drug Administration on Friday approved an altered dose of the drug Mylotarg to treat a distinctive type of acute myeloid leukemia – CD33-positive AML. An earlier version of the drug had been withdrawn from the market when health risks started to emerge. Known generically as gemtuzumab ozogamicin, the drug received the go-ahead to treat adults newly ...
FDA Approves Genentech’s Actemra (tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Posted 31 Aug 2017 by Drugs.com
South San Francisco, CA – August 30, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra® (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in patients two years of age and ...
First Gene Therapy Kymriah (tisagenlecleucel) Approved in U.S.
Posted 30 Aug 2017 by Drugs.com
WEDNESDAY, Aug. 30, 2017 – The U.S. Food and Drug Administration on Wednesday approved the first gene therapy in the United States, to treat children and young adults with a particularly tough type of leukemia. Kymriah (tisagenlecleucel) is for B-cell acute lymphoblastic leukemia (ALL), the agency said in a news release. "We're entering a new frontier in medical innovation with the ability to ...
FDA Approves Kymriah (tisagenlecleucel) CAR-T Gene Therapy for Acute Lymphoblastic Leukemia
Posted 30 Aug 2017 by Drugs.com
August 30, 2017 – The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases. The FDA approved Kymriah (tisagenlecleucel) for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL). ...
FDA Approves First Gene Therapy, Kymriah, for Use in U.S.
Posted 30 Aug 2017 by Drugs.com
WEDNESDAY, Aug. 30, 2017 – The U.S. Food and Drug Administration broke new ground in cancer care Wednesday by approving the first gene therapy for patients in the United States. Kymriah (tisagenlecleucel) genetically tweaks a patient's own immune system cells into what scientists call "a living drug" to battle a form of acute lymphoblastic leukemia (ALL). The immunotherapy now can be used in ...
FDA Approves Besponsa (inotuzumab ozogamicin) for Relapsed or Refractory Acute Lymphoblastic Leukemia
Posted 21 Aug 2017 by Drugs.com
August 17, 2017 – The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). “For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life expectancy is typically low,” said Richard Pazdur, M.D., dir ...
Ask a Question
Further Information
Related Condition Support Groups
Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Nonlymphocytic Leukemia, Hairy Cell Leukemia, Acute Myeloblastic Leukemia, Chronic Eosinophilic Leukemia, Meningeal Leukemia, Blood Disorders
Related Drug Support Groups
prednisone, triamcinolone, dexamethasone, Sprycel, Decadron, cytarabine, Deltasone, dasatinib, Kenalog-40, view more... Cytosar, Adrenocot LA, Sterapred DS, Liquid Pred, Adrenocot, Dexone, Cytosar-U, Sterapred, Fludara, Tarabine PFS, Prednicen-M, idarubicin, Prednicot, Clinacort, Idamycin, Dexamethasone Intensol, Oforta, fludarabine, Baycadron, Dalalone, Dalalone DP, Dalalone LA, Decaject, Decaject LA, Orasone, Idamycin PFS, Meticorten, Dexasone, Decadron-LA, Solurex LA, Dexacen-4, Solurex, De-Sone LA, Dexacort-LA, Dexasone LA, Hexadrol, Dexone LA, Primethasone, Dexacorten, Medidex, Medidex LA, Dexpak Taperpak, Zema Pak
